These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 9193325)

  • 1. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.
    Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
    J Clin Oncol; 1997 Apr; 15(4):1341-7. PubMed ID: 9193325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.
    Vehmanen L; Saarto T; Elomaa I; Mäkelä P; Välimäki M; Blomqvist C
    Eur J Cancer; 2001 Dec; 37(18):2373-8. PubMed ID: 11720830
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
    Fogelman I; Blake GM; Blamey R; Palmer M; Sauerbrei W; Schumacher M; Serin D; Stewart A; Wilpshaar W
    Osteoporos Int; 2003 Dec; 14(12):1001-6. PubMed ID: 14530912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Short-term intermittent intravenous clodronate in the prevention of bone loss related to chemotherapy-induced ovarian failure.
    Vehmanen L; Saarto T; Risteli J; Risteli L; Blomqvist C; Elomaa I
    Breast Cancer Res Treat; 2004 Sep; 87(2):181-8. PubMed ID: 15377842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-year oral clodronate treatment does not impair mineralization of newly formed bone--a histomorphometric study.
    Saarto T; Taube T; Blomqvist C; Vehmanen L; Elomaa I
    Calcif Tissue Int; 2005 Aug; 77(2):84-90. PubMed ID: 16075363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
    Jonat W; Kaufmann M; Sauerbrei W; Blamey R; Cuzick J; Namer M; Fogelman I; de Haes JC; de Matteis A; Stewart A; Eiermann W; Szakolczai I; Palmer M; Schumacher M; Geberth M; Lisboa B;
    J Clin Oncol; 2002 Dec; 20(24):4628-35. PubMed ID: 12488406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of clodronate and antioestrogens on bone loss associated with oestrogen withdrawal in postmenopausal women with breast cancer.
    Saarto T; Vehmanen L; Elomaa I; Välimäki M; Mäkelä P; Blomqvist C
    Br J Cancer; 2001 Apr; 84(8):1047-51. PubMed ID: 11308252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral clodronate and reduction in loss of bone mineral density in women with operable primary breast cancer.
    Powles TJ; McCloskey E; Paterson AH; Ashley S; Tidy VA; Nevantaus A; Rosenqvist K; Kanis J
    J Natl Cancer Inst; 1998 May; 90(9):704-8. PubMed ID: 9586668
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clodronate improves bone mineral density in post-menopausal breast cancer patients treated with adjuvant antioestrogens.
    Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
    Br J Cancer; 1997; 75(4):602-5. PubMed ID: 9052418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Premature ovarian failure and body composition changes with adjuvant chemotherapy for breast cancer.
    Gordon AM; Hurwitz S; Shapiro CL; LeBoff MS
    Menopause; 2011 Nov; 18(11):1244-8. PubMed ID: 21814159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
    Levine MN; Bramwell VH; Pritchard KI; Norris BD; Shepherd LE; Abu-Zahra H; Findlay B; Warr D; Bowman D; Myles J; Arnold A; Vandenberg T; MacKenzie R; Robert J; Ottaway J; Burnell M; Williams CK; Tu D
    J Clin Oncol; 1998 Aug; 16(8):2651-8. PubMed ID: 9704715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tamoxifen treatment after adjuvant chemotherapy has opposite effects on bone mineral density in premenopausal patients depending on menstrual status.
    Vehmanen L; Elomaa I; Blomqvist C; Saarto T
    J Clin Oncol; 2006 Feb; 24(4):675-80. PubMed ID: 16446340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide, methotrexate, and fluorouracil; oral cyclophosphamide; levamisole; or no adjuvant therapy for patients with high-risk, premenopausal breast cancer.
    Ejlertsen B; Mouridsen HT; Jensen MB; Andersen J; Andersson M; Kamby C; Knoop AS;
    Cancer; 2010 May; 116(9):2081-9. PubMed ID: 20186830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of oral clodronate on bone mineral density in patients with relapsing breast cancer.
    Rizzoli R; Forni M; Schaad MA; Slosman DO; Sappino AP; Garcia J; Bonjour JP
    Bone; 1996 Jun; 18(6):531-7. PubMed ID: 8805993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of ovarian dysfunction on bone mineral density in breast cancer patients 10 years after adjuvant chemotherapy.
    Vehmanen LK; Elomaa I; Blomqvist CP; Saarto T
    Acta Oncol; 2014 Jan; 53(1):75-9. PubMed ID: 23713891
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ten-year follow-up of 3 years of oral adjuvant clodronate therapy shows significant prevention of osteoporosis in early-stage breast cancer.
    Saarto T; Vehmanen L; Blomqvist C; Elomaa I
    J Clin Oncol; 2008 Sep; 26(26):4289-95. PubMed ID: 18779616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophosphamide, methotrexate and fluorouracil (CMF) versus hormonal ablation with leuprorelin acetate as adjuvant treatment of node-positive, premenopausal breast cancer patients: preliminary results of the TABLE-study (Takeda Adjuvant Breast cancer study with Leuprorelin Acetate).
    Schmid P; Untch M; Wallwiener D; Kossé V; Bondar G; Vassiljev L; Tarutinov V; Kienle E; Lüftner D; Possinger K;
    Anticancer Res; 2002; 22(4):2325-32. PubMed ID: 12174922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors.
    McCune JS; Games DM; Espirito JL
    J Oncol Pharm Pract; 2005 Jun; 11(2):37-43. PubMed ID: 16460603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
    Kim JE; Ahn JH; Jung KH; Kim SB; Kim HJ; Lee KS; Ro JS; Park YH; Ahn JS; Im YH; Im SA; Lee MH; Kim SY
    Breast Cancer Res Treat; 2011 Jan; 125(1):99-106. PubMed ID: 20922564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy.
    Dubsky P; Sevelda P; Jakesz R; Hausmaninger H; Samonigg H; Seifert M; Denison U; Mlineritsch B; Steger G; Kwasny W; Stöger H; Bartsch R; Stierer M; Taucher S; Fridrik M; Schippinger W; Greil R; Pötter R; Gnant M;
    Clin Cancer Res; 2008 Apr; 14(7):2082-7. PubMed ID: 18381948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.